MeiraGTx Holdings plc

MeiraGTx Holdings plc

8.05
EUR
0.00
(0.00%)
0.82EPS
14.41P/E
1.12BMarket Cap
Mar 18Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.4
0.41
0.85
0.35
0.25
0.48
1.01
4.75
Basic EPS, GAAP
-1.01
-3.62
-4.37
-1.65
-1.54
-1.8
-2.87
-1.49
-2.12
-1.42
0.94
Free Cash Flow per Basic Share
-0.88
-3.34
-3.7
0.33
-2.68
-1.49
-2.61
-2.22
-1.57
-0.63
-0.16
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.63
-1.74
2.96
5.19
5.4
4.16
2.43
2.17
0.87
-0.07
2.29
Tangible Book Value per Share
-0.63
-1.74
2.96
5.16
5.33
4.1
2.39
2.15
0.85
-0.08
2.28
Basic Weighted Avg Shares
19
9
19
33
38
44
45
56
70
80
84
Sales/Revenue/Turnover
- -
- -
- -
13
16
38
16
14
33
81
398
Operating Margin (%)
- -
- -
- -
-438.37
-401.94
-192.99
-730.87
-977.82
-493.44
-130.2
46.3
Depreciation Expense
- -
1
2
2
4
8
9
14
13
13
12
Net Income, GAAP
-19
-31
-83
-55
-58
-80
-130
-84
-148
-114
79
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.91
Profit Margin (%)
- -
- -
- -
-411.87
-372.63
-211.03
-814.16
-599.46
-444.1
-140.31
19.87
Working Capital
13
-10
59
220
218
115
72
93
63
-31
160
LT Debt
- -
- -
- -
22
20
20
88
85
81
61
110
Total Equity
-17
-47
81
191
239
185
118
138
68
-6
216
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
86.34
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
44.3
Return on Common Equity (%)
- -
- -
- -
-40.28
-27.01
-37.53
-85.52
-65.67
-143.48
- -
72.28

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
28
27
2
LT Borrowings
50
50
100
LT Finance Leases
11
11
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
94
Market Capitalization
624
711
1,281

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
92
96
218
Cash, Cash Equivalents & STI
66
72
143
Accounts Receivable, Net
3
3
6
Inventories
- -
- -
- -
Total Current Liabilities
123
176
58
Payables & Accruals
30
31
26
ST Debt
28
27
2
Deferred Revenue
2
2
5

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-40.17%
-108.54%
Free Cash Flow
- -
-3.12%
-53.77%
Net Income, GAAP
- -
23.62%
-22.73%
Sales/Revenue/Turnover
- -
70.9%
144.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
- -
11
21
33
2025
2
4
- -
75
81
2026
- -
321
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.32
-0.76
-0.55
-0.5
-2.12
2025
-0.51
-0.48
-0.62
0.19
-1.42
2026
-0.57
1.76
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Alexandria Forbes
Full Time Employees
403
Sector
Health technology
Industry
Biotechnology
Address
655 Third Avenue New York NY United States 10017
IPO Date
Jun 8, 2018
Business
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company focused on developing novel gene therapies for rare and prevalent diseases in ophthalmology, salivary gland disorders, neurodegenerative conditions, and metabolic diseases. Founded in 2015 and headquartered in New York, New York, with additional manufacturing facilities in the United Kingdom and Ireland, the company advances a broad pipeline supported by proprietary viral vector optimization, end-to-end GMP manufacturing capabilities, and riboswitch gene regulation technology for precise, dose-responsive control of gene expression via oral small molecules. Core programs include AAV-AQP1 for radiation-induced xerostomia (Phase 3-ready) and Sjogren’s disease (preclinical); AAV-GAD for Parkinson’s disease (Phase 3-ready, with FDA RMAT designation); botaretigene sparoparvovec (AAV-RPGR) for X-linked retinitis pigmentosa (Phase 3 completed, subject to asset purchase agreement with Janssen); AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4 (specials license in the UK, pursuing expedited approvals); preclinical ophthalmology candidates such as AAV-RDH12 for RDH12-associated retinal dystrophy, AAV-ABCA4 for Stargardt’s disease, AAV-VEGFR2 for wet AMD, and undisclosed programs for dry AMD/GA and Bardet-Biedl syndrome; riboswitch-regulated therapies including RiboLeptin for lipodystrophies, undisclosed candidates for intractable neuropathic pain and GLP-1/GIP combinations for obesity/MASH/metabolic disease, and Ribo-CAR-T for oncology and autoimmune diseases; as well as AAV-BDNF for MC4R/BDNF genetic obesity and preclinical neurodegenerative programs like AAV-UPF1/AAV-CNTFR for ALS. Geographically, MeiraGTx operates primarily in the United States, United Kingdom, and European Union, targeting patients with serious unmet needs in these therapeutic areas. Recent developments include a March 2025 strategic collaboration with Hologen AI featuring a $200 million upfront payment and formation of Hologen Neuro AI Ltd joint venture with up to $230 million committed capital to accelerate Phase 3 development of AAV-GAD for Parkinson’s disease, industrialize manufacturing, and advance CNS programs; FDA RMAT designations for AAV-GAD (May 2025) and AAV2-hAQP1 for xerostomia (January 2025); publication of landmark efficacy data in The Lancet for AAV-AIPL1 restoring vision in 11 children blind from birth (February 2025), prompting MAA filing in the UK and U.S. discussions; alignment with FDA on the pivotal Phase 2 AQUAx2 study for xerostomia (2025); an asset purchase agreement with Janssen for up to $415 million covering botaretigene sparoparvovec (announced earlier); and multiple Rare Pediatric Disease Designations for inherited retinal programs.

Company News

  • MeiraGTx Announces Oral Presentation at ObesityWeek 2026

  • MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

  • MeiraGTx Reports Third Quarter 2026 Financial and Operational Results

  • MeiraGTx Holdings PLC $MGTX Shares Acquired by Alps Advisors Inc.

  • MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

  • Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)

  • MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

  • Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)

  • Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

  • Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

  • MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

  • MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

  • Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

  • MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Some Potential Merit Within MeiraGTx Holdings

  • Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?

  • What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

  • MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?

  • MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

  • MeiraGTx: The Market Is Missing The Manufacturing Pivot